A better understanding of the complex physiology of weight regulation and the role of intestinal hormones in regulating food intake, appetite, and glucose homeostasis led to the discovery of GLP- 1 receptor analogs as safe and effective treatments, initially for T2DM and more recently in higher doses to treat obesity (liraglutide 3 mg and semaglutide 2.4 mg)
On the other hand, in the SUSTAIN 6 trial, the effects on plasma lipids of the most powerful of the GLP-1RAs, semaglutide, were not remarkable
Follow-up check-ins occur at weeks 2, 4, and 8 to monitor tolerance and adjust dosing as needed
In this study, the results of flow cytometry, immunofluorescence staining, RT-qPCR and ELISA assays demonstrated that GLP-1RAs could drive macrophage polarization towards the M2 type, thereby inhibiting the continuous development of synovitis
As a result, clinicians are exploring whether these drugs can complement insulin therapy rather than replace it
(2023) 102:E35394